Q2 EPS Forecast for Milestone Pharmaceuticals Cut by Analyst

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) – Analysts at HC Wainwright dropped their Q2 2026 EPS estimates for shares of Milestone Pharmaceuticals in a research report issued on Wednesday, May 13th. HC Wainwright analyst B. Folkes now forecasts that the company will earn ($0.19) per share for the quarter, down from their prior estimate of ($0.18). The consensus estimate for Milestone Pharmaceuticals’ current full-year earnings is ($0.96) per share. HC Wainwright also issued estimates for Milestone Pharmaceuticals’ Q3 2026 earnings at ($0.19) EPS, Q4 2026 earnings at ($0.21) EPS, FY2026 earnings at ($0.78) EPS, FY2027 earnings at ($0.79) EPS and FY2029 earnings at $1.08 EPS.

A number of other equities analysts have also commented on the stock. Wall Street Zen lowered shares of Milestone Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Sunday. Raymond James Financial assumed coverage on shares of Milestone Pharmaceuticals in a report on Friday, April 10th. They issued a “strong-buy” rating and a $6.00 price target on the stock. Wells Fargo & Company decreased their price target on shares of Milestone Pharmaceuticals from $8.00 to $7.00 and set an “overweight” rating on the stock in a report on Thursday, May 14th. Finally, Zacks Research lowered shares of Milestone Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Friday. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $7.25.

Milestone Pharmaceuticals Price Performance

Shares of NASDAQ:MIST opened at $1.46 on Tuesday. The company’s fifty day moving average price is $1.70 and its 200-day moving average price is $1.92. The firm has a market capitalization of $181.77 million, a price-to-earnings ratio of -2.15 and a beta of 1.04. Milestone Pharmaceuticals has a one year low of $1.00 and a one year high of $3.06. The company has a debt-to-equity ratio of 1.61, a current ratio of 9.18 and a quick ratio of 9.09.

Milestone Pharmaceuticals (NASDAQ:MIST) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.26). The firm had revenue of $0.24 million for the quarter, compared to analysts’ expectations of $30.12 million.

Hedge Funds Weigh In On Milestone Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the business. Propel Bio Management LLC grew its holdings in shares of Milestone Pharmaceuticals by 186.1% during the 3rd quarter. Propel Bio Management LLC now owns 5,124,890 shares of the company’s stock valued at $10,250,000 after purchasing an additional 3,333,333 shares during the last quarter. Orbimed Advisors LLC bought a new position in shares of Milestone Pharmaceuticals during the 3rd quarter valued at $6,444,000. Marshall Wace LLP grew its holdings in shares of Milestone Pharmaceuticals by 289.8% during the 4th quarter. Marshall Wace LLP now owns 1,656,821 shares of the company’s stock valued at $3,347,000 after purchasing an additional 1,231,793 shares during the last quarter. Pathstone Holdings LLC bought a new position in shares of Milestone Pharmaceuticals during the 3rd quarter valued at $2,000,000. Finally, Boxer Capital Management LLC bought a new position in shares of Milestone Pharmaceuticals during the 3rd quarter valued at $1,333,000. Institutional investors own 86.18% of the company’s stock.

Insider Activity at Milestone Pharmaceuticals

In related news, CEO Joseph Oliveto sold 36,500 shares of the stock in a transaction on Thursday, April 16th. The shares were sold at an average price of $2.26, for a total transaction of $82,490.00. Following the transaction, the chief executive officer owned 446,244 shares of the company’s stock, valued at approximately $1,008,511.44. This trade represents a 7.56% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 19.50% of the company’s stock.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.